Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(23):1873-1876; doi:10.1093/jnci/92.23.1873
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 23, 1873-1876, December 6, 2000
© 2000 Oxford University Press

NEWS

Prostate Cancer: Numbers May Not Tell the Whole Story

Tom Reynolds

In prostate cancer, as anywhere, statistics can fool the unwary—so careful researchers, physicians, and patients must look beyond the numbers to get the whole truth, according to Michael J. Barry, M.D., of Massachusetts General Hospital in Boston.



View larger version (108K):
[in this window]
[in a new window]
  		Dr. Michael J. Barry

 
Barry, a primary-care physician, researcher, and advocate of evidence-based medicine, discussed beliefs and evidence about prostate cancer screening and treatment at the American Society of Therapeutic Radiation and Oncology’s annual meeting, held in Boston in October.

Key Factor

One key factor in interpreting prostate cancer treatment outcome data is the lead-time bias introduced in the last decade by prostate-specific antigen (PSA) screening. Prostate cancer is typically a slow-growing disease, and early diagnosis with PSA . . . [Full Text of this Article]

Side Effects of Treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. R. Husain, K. Kawakami, M. Kawakami, and R. K. Puri
Interleukin-4 Receptor-targeted Cytotoxin Therapy of Androgen-dependent and -independent Prostate Carcinoma in Xenograft Models
Mol. Cancer Ther., March 1, 2003; 2(3): 245 - 254.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. Crocetti, S. Ciatto, and M. Zappa
Prostate Cancer: Different Incidence But Not Mortality Trends Within Two Areas of Tuscany, Italy
J Natl Cancer Inst, June 6, 2001; 93(11): 876a - 877a.
[Full Text] [PDF]